Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
17,819
archived clinical trials in
Brain Cancer

A Clinical Study Conducted in Multiple Centers Comparing Veliparib and Whole Brain Radiation Therapy (WBRT) Versus Placebo and WBRT in Subjects With Brain Metastases From Non Small Cell Lung Cancer (NSCLC)
A Randomized, Double-Blind, Phase 2, Dose-Ranging Study to Evaluate the Safety and Efficacy of Veliparib and Whole Brain Radiation Therapy Versus Placebo and Whole Brain Radiation Therapy in Subjects With Brain Metastases From Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  1/22/2016
Clinical Research Facility
mi
from
Cleveland, OH
A Clinical Study Conducted in Multiple Centers Comparing Veliparib and Whole Brain Radiation Therapy (WBRT) Versus Placebo and WBRT in Subjects With Brain Metastases From Non Small Cell Lung Cancer (NSCLC)
A Randomized, Double-Blind, Phase 2, Dose-Ranging Study to Evaluate the Safety and Efficacy of Veliparib and Whole Brain Radiation Therapy Versus Placebo and Whole Brain Radiation Therapy in Subjects With Brain Metastases From Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 1/22/2016
Clinical Research Facility
mi
from
Cleveland, OH
Click here to add this to my saved trials
A Clinical Study Conducted in Multiple Centers Comparing Veliparib and Whole Brain Radiation Therapy (WBRT) Versus Placebo and WBRT in Subjects With Brain Metastases From Non Small Cell Lung Cancer (NSCLC)
A Randomized, Double-Blind, Phase 2, Dose-Ranging Study to Evaluate the Safety and Efficacy of Veliparib and Whole Brain Radiation Therapy Versus Placebo and Whole Brain Radiation Therapy in Subjects With Brain Metastases From Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  1/22/2016
Clinical Research Facility
mi
from
Cleveland, OH
A Clinical Study Conducted in Multiple Centers Comparing Veliparib and Whole Brain Radiation Therapy (WBRT) Versus Placebo and WBRT in Subjects With Brain Metastases From Non Small Cell Lung Cancer (NSCLC)
A Randomized, Double-Blind, Phase 2, Dose-Ranging Study to Evaluate the Safety and Efficacy of Veliparib and Whole Brain Radiation Therapy Versus Placebo and Whole Brain Radiation Therapy in Subjects With Brain Metastases From Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 1/22/2016
Clinical Research Facility
mi
from
Cleveland, OH
Click here to add this to my saved trials
A Clinical Study Conducted in Multiple Centers Comparing Veliparib and Whole Brain Radiation Therapy (WBRT) Versus Placebo and WBRT in Subjects With Brain Metastases From Non Small Cell Lung Cancer (NSCLC)
A Randomized, Double-Blind, Phase 2, Dose-Ranging Study to Evaluate the Safety and Efficacy of Veliparib and Whole Brain Radiation Therapy Versus Placebo and Whole Brain Radiation Therapy in Subjects With Brain Metastases From Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  1/22/2016
Clinical Research Facility
mi
from
Philadelphia, PA
A Clinical Study Conducted in Multiple Centers Comparing Veliparib and Whole Brain Radiation Therapy (WBRT) Versus Placebo and WBRT in Subjects With Brain Metastases From Non Small Cell Lung Cancer (NSCLC)
A Randomized, Double-Blind, Phase 2, Dose-Ranging Study to Evaluate the Safety and Efficacy of Veliparib and Whole Brain Radiation Therapy Versus Placebo and Whole Brain Radiation Therapy in Subjects With Brain Metastases From Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 1/22/2016
Clinical Research Facility
mi
from
Philadelphia, PA
Click here to add this to my saved trials
A Clinical Study Conducted in Multiple Centers Comparing Veliparib and Whole Brain Radiation Therapy (WBRT) Versus Placebo and WBRT in Subjects With Brain Metastases From Non Small Cell Lung Cancer (NSCLC)
A Randomized, Double-Blind, Phase 2, Dose-Ranging Study to Evaluate the Safety and Efficacy of Veliparib and Whole Brain Radiation Therapy Versus Placebo and Whole Brain Radiation Therapy in Subjects With Brain Metastases From Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  1/22/2016
Clinical Research Facility
mi
from
Philadelphia, PA
A Clinical Study Conducted in Multiple Centers Comparing Veliparib and Whole Brain Radiation Therapy (WBRT) Versus Placebo and WBRT in Subjects With Brain Metastases From Non Small Cell Lung Cancer (NSCLC)
A Randomized, Double-Blind, Phase 2, Dose-Ranging Study to Evaluate the Safety and Efficacy of Veliparib and Whole Brain Radiation Therapy Versus Placebo and Whole Brain Radiation Therapy in Subjects With Brain Metastases From Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 1/22/2016
Clinical Research Facility
mi
from
Philadelphia, PA
Click here to add this to my saved trials
A Clinical Study Conducted in Multiple Centers Comparing Veliparib and Whole Brain Radiation Therapy (WBRT) Versus Placebo and WBRT in Subjects With Brain Metastases From Non Small Cell Lung Cancer (NSCLC)
A Randomized, Double-Blind, Phase 2, Dose-Ranging Study to Evaluate the Safety and Efficacy of Veliparib and Whole Brain Radiation Therapy Versus Placebo and Whole Brain Radiation Therapy in Subjects With Brain Metastases From Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  1/22/2016
Clinical Research Facility
mi
from
Philadelphia, PA
A Clinical Study Conducted in Multiple Centers Comparing Veliparib and Whole Brain Radiation Therapy (WBRT) Versus Placebo and WBRT in Subjects With Brain Metastases From Non Small Cell Lung Cancer (NSCLC)
A Randomized, Double-Blind, Phase 2, Dose-Ranging Study to Evaluate the Safety and Efficacy of Veliparib and Whole Brain Radiation Therapy Versus Placebo and Whole Brain Radiation Therapy in Subjects With Brain Metastases From Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 1/22/2016
Clinical Research Facility
mi
from
Philadelphia, PA
Click here to add this to my saved trials
A Clinical Study Conducted in Multiple Centers Comparing Veliparib and Whole Brain Radiation Therapy (WBRT) Versus Placebo and WBRT in Subjects With Brain Metastases From Non Small Cell Lung Cancer (NSCLC)
A Randomized, Double-Blind, Phase 2, Dose-Ranging Study to Evaluate the Safety and Efficacy of Veliparib and Whole Brain Radiation Therapy Versus Placebo and Whole Brain Radiation Therapy in Subjects With Brain Metastases From Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  1/22/2016
Clinical Research Facility
mi
from
Philadelphia, PA
A Clinical Study Conducted in Multiple Centers Comparing Veliparib and Whole Brain Radiation Therapy (WBRT) Versus Placebo and WBRT in Subjects With Brain Metastases From Non Small Cell Lung Cancer (NSCLC)
A Randomized, Double-Blind, Phase 2, Dose-Ranging Study to Evaluate the Safety and Efficacy of Veliparib and Whole Brain Radiation Therapy Versus Placebo and Whole Brain Radiation Therapy in Subjects With Brain Metastases From Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 1/22/2016
Clinical Research Facility
mi
from
Philadelphia, PA
Click here to add this to my saved trials
A Clinical Study Conducted in Multiple Centers Comparing Veliparib and Whole Brain Radiation Therapy (WBRT) Versus Placebo and WBRT in Subjects With Brain Metastases From Non Small Cell Lung Cancer (NSCLC)
A Randomized, Double-Blind, Phase 2, Dose-Ranging Study to Evaluate the Safety and Efficacy of Veliparib and Whole Brain Radiation Therapy Versus Placebo and Whole Brain Radiation Therapy in Subjects With Brain Metastases From Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  1/22/2016
Clinical Research Facility
mi
from
Providence, RI
A Clinical Study Conducted in Multiple Centers Comparing Veliparib and Whole Brain Radiation Therapy (WBRT) Versus Placebo and WBRT in Subjects With Brain Metastases From Non Small Cell Lung Cancer (NSCLC)
A Randomized, Double-Blind, Phase 2, Dose-Ranging Study to Evaluate the Safety and Efficacy of Veliparib and Whole Brain Radiation Therapy Versus Placebo and Whole Brain Radiation Therapy in Subjects With Brain Metastases From Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 1/22/2016
Clinical Research Facility
mi
from
Providence, RI
Click here to add this to my saved trials
A Clinical Study Conducted in Multiple Centers Comparing Veliparib and Whole Brain Radiation Therapy (WBRT) Versus Placebo and WBRT in Subjects With Brain Metastases From Non Small Cell Lung Cancer (NSCLC)
A Randomized, Double-Blind, Phase 2, Dose-Ranging Study to Evaluate the Safety and Efficacy of Veliparib and Whole Brain Radiation Therapy Versus Placebo and Whole Brain Radiation Therapy in Subjects With Brain Metastases From Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  1/22/2016
Clinical Research Facility
mi
from
Arlington, TX
A Clinical Study Conducted in Multiple Centers Comparing Veliparib and Whole Brain Radiation Therapy (WBRT) Versus Placebo and WBRT in Subjects With Brain Metastases From Non Small Cell Lung Cancer (NSCLC)
A Randomized, Double-Blind, Phase 2, Dose-Ranging Study to Evaluate the Safety and Efficacy of Veliparib and Whole Brain Radiation Therapy Versus Placebo and Whole Brain Radiation Therapy in Subjects With Brain Metastases From Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 1/22/2016
Clinical Research Facility
mi
from
Arlington, TX
Click here to add this to my saved trials
A Clinical Study Conducted in Multiple Centers Comparing Veliparib and Whole Brain Radiation Therapy (WBRT) Versus Placebo and WBRT in Subjects With Brain Metastases From Non Small Cell Lung Cancer (NSCLC)
A Randomized, Double-Blind, Phase 2, Dose-Ranging Study to Evaluate the Safety and Efficacy of Veliparib and Whole Brain Radiation Therapy Versus Placebo and Whole Brain Radiation Therapy in Subjects With Brain Metastases From Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  1/22/2016
Clinical Research Facility
mi
from
Arlington, TX
A Clinical Study Conducted in Multiple Centers Comparing Veliparib and Whole Brain Radiation Therapy (WBRT) Versus Placebo and WBRT in Subjects With Brain Metastases From Non Small Cell Lung Cancer (NSCLC)
A Randomized, Double-Blind, Phase 2, Dose-Ranging Study to Evaluate the Safety and Efficacy of Veliparib and Whole Brain Radiation Therapy Versus Placebo and Whole Brain Radiation Therapy in Subjects With Brain Metastases From Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 1/22/2016
Clinical Research Facility
mi
from
Arlington, TX
Click here to add this to my saved trials
A Clinical Study Conducted in Multiple Centers Comparing Veliparib and Whole Brain Radiation Therapy (WBRT) Versus Placebo and WBRT in Subjects With Brain Metastases From Non Small Cell Lung Cancer (NSCLC)
A Randomized, Double-Blind, Phase 2, Dose-Ranging Study to Evaluate the Safety and Efficacy of Veliparib and Whole Brain Radiation Therapy Versus Placebo and Whole Brain Radiation Therapy in Subjects With Brain Metastases From Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  1/22/2016
Clinical Research Facility
mi
from
Dallas, TX
A Clinical Study Conducted in Multiple Centers Comparing Veliparib and Whole Brain Radiation Therapy (WBRT) Versus Placebo and WBRT in Subjects With Brain Metastases From Non Small Cell Lung Cancer (NSCLC)
A Randomized, Double-Blind, Phase 2, Dose-Ranging Study to Evaluate the Safety and Efficacy of Veliparib and Whole Brain Radiation Therapy Versus Placebo and Whole Brain Radiation Therapy in Subjects With Brain Metastases From Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 1/22/2016
Clinical Research Facility
mi
from
Dallas, TX
Click here to add this to my saved trials
A Clinical Study Conducted in Multiple Centers Comparing Veliparib and Whole Brain Radiation Therapy (WBRT) Versus Placebo and WBRT in Subjects With Brain Metastases From Non Small Cell Lung Cancer (NSCLC)
A Randomized, Double-Blind, Phase 2, Dose-Ranging Study to Evaluate the Safety and Efficacy of Veliparib and Whole Brain Radiation Therapy Versus Placebo and Whole Brain Radiation Therapy in Subjects With Brain Metastases From Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  1/22/2016
Site Reference ID/Investigator# 68563
mi
from
Rosario, Santa Fe,
A Clinical Study Conducted in Multiple Centers Comparing Veliparib and Whole Brain Radiation Therapy (WBRT) Versus Placebo and WBRT in Subjects With Brain Metastases From Non Small Cell Lung Cancer (NSCLC)
A Randomized, Double-Blind, Phase 2, Dose-Ranging Study to Evaluate the Safety and Efficacy of Veliparib and Whole Brain Radiation Therapy Versus Placebo and Whole Brain Radiation Therapy in Subjects With Brain Metastases From Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 1/22/2016
Site Reference ID/Investigator# 68563
mi
from
Rosario, Santa Fe,
Click here to add this to my saved trials
Phase II Trial of Stereotactic Radiosurgery Boost Following Surgical Resection for Brain Metastases
Phase II Trial of Stereotactic Radiosurgery Boost Following Surgical Resection for Brain Metastases
Status: Enrolling
Updated:  1/22/2016
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Phase II Trial of Stereotactic Radiosurgery Boost Following Surgical Resection for Brain Metastases
Phase II Trial of Stereotactic Radiosurgery Boost Following Surgical Resection for Brain Metastases
Status: Enrolling
Updated: 1/22/2016
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Click here to add this to my saved trials
Study of Peptide Vaccination With Tumor Associated Antigens Mixed With Montanide in Patients With CNS Tumors
A Phase I Study of Peptide Vaccination With Tumor Associated Antigens Mixed With Montanide ISA-51VG in Pediatric Patients With Recurrent or Refractory Central Nervous System Tumors
Status: Enrolling
Updated:  1/25/2016
NYU Langone Medical Center
mi
from
New York, NY
Study of Peptide Vaccination With Tumor Associated Antigens Mixed With Montanide in Patients With CNS Tumors
A Phase I Study of Peptide Vaccination With Tumor Associated Antigens Mixed With Montanide ISA-51VG in Pediatric Patients With Recurrent or Refractory Central Nervous System Tumors
Status: Enrolling
Updated: 1/25/2016
NYU Langone Medical Center
mi
from
New York, NY
Click here to add this to my saved trials
Phase II NKTR-102 In Bevacizumab-Resistant High Grade Glioma
A Phase II, Single Arm, Open Label Study Of NKTR-102 In Bevacizumab-Resistant High Grade Glioma
Status: Enrolling
Updated:  1/25/2016
Stanford University School of Medicine
mi
from
Palo Alto, CA
Phase II NKTR-102 In Bevacizumab-Resistant High Grade Glioma
A Phase II, Single Arm, Open Label Study Of NKTR-102 In Bevacizumab-Resistant High Grade Glioma
Status: Enrolling
Updated: 1/25/2016
Stanford University School of Medicine
mi
from
Palo Alto, CA
Click here to add this to my saved trials
Sorafenib in Children and Young Adults With Recurrent or Progressive Low-Grade Astrocytomas
Phase II Study of Sorafenib in Children and Young Adults With Recurrent or Progressive Low-Grade Astrocytomas
Status: Enrolling
Updated:  1/25/2016
New York University Stephen D. Hassenfeld Children's Center for Cancer & Blood Disorders
mi
from
New York, NY
Sorafenib in Children and Young Adults With Recurrent or Progressive Low-Grade Astrocytomas
Phase II Study of Sorafenib in Children and Young Adults With Recurrent or Progressive Low-Grade Astrocytomas
Status: Enrolling
Updated: 1/25/2016
New York University Stephen D. Hassenfeld Children's Center for Cancer & Blood Disorders
mi
from
New York, NY
Click here to add this to my saved trials
Laser Ablation After Stereotactic Radiosurgery
Laser Ablation After Stereotactic Radiosurgery
Status: Enrolling
Updated:  1/27/2016
Yale School of Medicine
mi
from
New Haven, CT
Laser Ablation After Stereotactic Radiosurgery
Laser Ablation After Stereotactic Radiosurgery
Status: Enrolling
Updated: 1/27/2016
Yale School of Medicine
mi
from
New Haven, CT
Click here to add this to my saved trials
Laser Ablation After Stereotactic Radiosurgery
Laser Ablation After Stereotactic Radiosurgery
Status: Enrolling
Updated:  1/27/2016
Kansas University Medical Center
mi
from
Kansas City, KA
Laser Ablation After Stereotactic Radiosurgery
Laser Ablation After Stereotactic Radiosurgery
Status: Enrolling
Updated: 1/27/2016
Kansas University Medical Center
mi
from
Kansas City, KA
Click here to add this to my saved trials
Laser Ablation After Stereotactic Radiosurgery
Laser Ablation After Stereotactic Radiosurgery
Status: Enrolling
Updated:  1/27/2016
Carolina NeuroSurgery & Spine Associates
mi
from
Charlotte, NC
Laser Ablation After Stereotactic Radiosurgery
Laser Ablation After Stereotactic Radiosurgery
Status: Enrolling
Updated: 1/27/2016
Carolina NeuroSurgery & Spine Associates
mi
from
Charlotte, NC
Click here to add this to my saved trials
Laser Ablation After Stereotactic Radiosurgery
Laser Ablation After Stereotactic Radiosurgery
Status: Enrolling
Updated:  1/27/2016
Wake Forest School of Medicine
mi
from
Winston-Salem, NC
Laser Ablation After Stereotactic Radiosurgery
Laser Ablation After Stereotactic Radiosurgery
Status: Enrolling
Updated: 1/27/2016
Wake Forest School of Medicine
mi
from
Winston-Salem, NC
Click here to add this to my saved trials
Laser Ablation After Stereotactic Radiosurgery
Laser Ablation After Stereotactic Radiosurgery
Status: Enrolling
Updated:  1/27/2016
Cleveland Clinic
mi
from
Cleveland, OH
Laser Ablation After Stereotactic Radiosurgery
Laser Ablation After Stereotactic Radiosurgery
Status: Enrolling
Updated: 1/27/2016
Cleveland Clinic
mi
from
Cleveland, OH
Click here to add this to my saved trials
Laser Ablation After Stereotactic Radiosurgery
Laser Ablation After Stereotactic Radiosurgery
Status: Enrolling
Updated:  1/27/2016
Thomas Jefferson University
mi
from
Philadelphia, PA
Laser Ablation After Stereotactic Radiosurgery
Laser Ablation After Stereotactic Radiosurgery
Status: Enrolling
Updated: 1/27/2016
Thomas Jefferson University
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Laser Ablation After Stereotactic Radiosurgery
Laser Ablation After Stereotactic Radiosurgery
Status: Enrolling
Updated:  1/27/2016
Washington University, St. Louis
mi
from
St. Louis, MO
Laser Ablation After Stereotactic Radiosurgery
Laser Ablation After Stereotactic Radiosurgery
Status: Enrolling
Updated: 1/27/2016
Washington University, St. Louis
mi
from
St. Louis, MO
Click here to add this to my saved trials
Vismodegib in Treating Patients With Recurrent or Refractory Medulloblastoma
A Phase II Clinical Trial Evaluating the Efficacy and Safety of GDC-0449 in Adults With Recurrent or Refractory Medulloblastoma
Status: Enrolling
Updated:  1/28/2016
Childrens National Medical Center
mi
from
Washington,
Vismodegib in Treating Patients With Recurrent or Refractory Medulloblastoma
A Phase II Clinical Trial Evaluating the Efficacy and Safety of GDC-0449 in Adults With Recurrent or Refractory Medulloblastoma
Status: Enrolling
Updated: 1/28/2016
Childrens National Medical Center
mi
from
Washington,
Click here to add this to my saved trials
Vismodegib in Treating Patients With Recurrent or Refractory Medulloblastoma
A Phase II Clinical Trial Evaluating the Efficacy and Safety of GDC-0449 in Adults With Recurrent or Refractory Medulloblastoma
Status: Enrolling
Updated:  1/28/2016
Duke Univ Med Ctr
mi
from
Durham, NC
Vismodegib in Treating Patients With Recurrent or Refractory Medulloblastoma
A Phase II Clinical Trial Evaluating the Efficacy and Safety of GDC-0449 in Adults With Recurrent or Refractory Medulloblastoma
Status: Enrolling
Updated: 1/28/2016
Duke Univ Med Ctr
mi
from
Durham, NC
Click here to add this to my saved trials
Vismodegib in Treating Patients With Recurrent or Refractory Medulloblastoma
A Phase II Clinical Trial Evaluating the Efficacy and Safety of GDC-0449 in Adults With Recurrent or Refractory Medulloblastoma
Status: Enrolling
Updated:  1/28/2016
Children's Hospital of Philadelphia
mi
from
Philadelphia, PA
Vismodegib in Treating Patients With Recurrent or Refractory Medulloblastoma
A Phase II Clinical Trial Evaluating the Efficacy and Safety of GDC-0449 in Adults With Recurrent or Refractory Medulloblastoma
Status: Enrolling
Updated: 1/28/2016
Children's Hospital of Philadelphia
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Vismodegib in Treating Patients With Recurrent or Refractory Medulloblastoma
A Phase II Clinical Trial Evaluating the Efficacy and Safety of GDC-0449 in Adults With Recurrent or Refractory Medulloblastoma
Status: Enrolling
Updated:  1/28/2016
Children's Hospital of Pittsburgh of UPMC
mi
from
Pittsburgh, PA
Vismodegib in Treating Patients With Recurrent or Refractory Medulloblastoma
A Phase II Clinical Trial Evaluating the Efficacy and Safety of GDC-0449 in Adults With Recurrent or Refractory Medulloblastoma
Status: Enrolling
Updated: 1/28/2016
Children's Hospital of Pittsburgh of UPMC
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
Vismodegib in Treating Patients With Recurrent or Refractory Medulloblastoma
A Phase II Clinical Trial Evaluating the Efficacy and Safety of GDC-0449 in Adults With Recurrent or Refractory Medulloblastoma
Status: Enrolling
Updated:  1/28/2016
St. Jude Children's Research Hospital
mi
from
Memphis, TN
Vismodegib in Treating Patients With Recurrent or Refractory Medulloblastoma
A Phase II Clinical Trial Evaluating the Efficacy and Safety of GDC-0449 in Adults With Recurrent or Refractory Medulloblastoma
Status: Enrolling
Updated: 1/28/2016
St. Jude Children's Research Hospital
mi
from
Memphis, TN
Click here to add this to my saved trials
Vismodegib in Treating Patients With Recurrent or Refractory Medulloblastoma
A Phase II Clinical Trial Evaluating the Efficacy and Safety of GDC-0449 in Adults With Recurrent or Refractory Medulloblastoma
Status: Enrolling
Updated:  1/28/2016
Childrens Hospital Los Angeles
mi
from
Los Angeles, CA
Vismodegib in Treating Patients With Recurrent or Refractory Medulloblastoma
A Phase II Clinical Trial Evaluating the Efficacy and Safety of GDC-0449 in Adults With Recurrent or Refractory Medulloblastoma
Status: Enrolling
Updated: 1/28/2016
Childrens Hospital Los Angeles
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Vismodegib in Treating Patients With Recurrent or Refractory Medulloblastoma
A Phase II Clinical Trial Evaluating the Efficacy and Safety of GDC-0449 in Adults With Recurrent or Refractory Medulloblastoma
Status: Enrolling
Updated:  1/28/2016
Lucile Packard Children's Hospital Stanford University
mi
from
Palo Alto, CA
Vismodegib in Treating Patients With Recurrent or Refractory Medulloblastoma
A Phase II Clinical Trial Evaluating the Efficacy and Safety of GDC-0449 in Adults With Recurrent or Refractory Medulloblastoma
Status: Enrolling
Updated: 1/28/2016
Lucile Packard Children's Hospital Stanford University
mi
from
Palo Alto, CA
Click here to add this to my saved trials
Vismodegib in Treating Patients With Recurrent or Refractory Medulloblastoma
A Phase II Clinical Trial Evaluating the Efficacy and Safety of GDC-0449 in Adults With Recurrent or Refractory Medulloblastoma
Status: Enrolling
Updated:  1/28/2016
UCSF Medical Center at Mount Zion
mi
from
San Francisco, CA
Vismodegib in Treating Patients With Recurrent or Refractory Medulloblastoma
A Phase II Clinical Trial Evaluating the Efficacy and Safety of GDC-0449 in Adults With Recurrent or Refractory Medulloblastoma
Status: Enrolling
Updated: 1/28/2016
UCSF Medical Center at Mount Zion
mi
from
San Francisco, CA
Click here to add this to my saved trials
Vismodegib in Treating Patients With Recurrent or Refractory Medulloblastoma
A Phase II Clinical Trial Evaluating the Efficacy and Safety of GDC-0449 in Adults With Recurrent or Refractory Medulloblastoma
Status: Enrolling
Updated:  1/28/2016
Lurie Children's Hospital- Chicago
mi
from
Chicago, IL
Vismodegib in Treating Patients With Recurrent or Refractory Medulloblastoma
A Phase II Clinical Trial Evaluating the Efficacy and Safety of GDC-0449 in Adults With Recurrent or Refractory Medulloblastoma
Status: Enrolling
Updated: 1/28/2016
Lurie Children's Hospital- Chicago
mi
from
Chicago, IL
Click here to add this to my saved trials
Vismodegib in Treating Patients With Recurrent or Refractory Medulloblastoma
A Phase II Clinical Trial Evaluating the Efficacy and Safety of GDC-0449 in Adults With Recurrent or Refractory Medulloblastoma
Status: Enrolling
Updated:  1/28/2016
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Vismodegib in Treating Patients With Recurrent or Refractory Medulloblastoma
A Phase II Clinical Trial Evaluating the Efficacy and Safety of GDC-0449 in Adults With Recurrent or Refractory Medulloblastoma
Status: Enrolling
Updated: 1/28/2016
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Click here to add this to my saved trials
Vismodegib in Treating Patients With Recurrent or Refractory Medulloblastoma
A Phase II Clinical Trial Evaluating the Efficacy and Safety of GDC-0449 in Adults With Recurrent or Refractory Medulloblastoma
Status: Enrolling
Updated:  1/28/2016
Cincinnati Children's Hospital Medical Center
mi
from
Cincinnati, OH
Vismodegib in Treating Patients With Recurrent or Refractory Medulloblastoma
A Phase II Clinical Trial Evaluating the Efficacy and Safety of GDC-0449 in Adults With Recurrent or Refractory Medulloblastoma
Status: Enrolling
Updated: 1/28/2016
Cincinnati Children's Hospital Medical Center
mi
from
Cincinnati, OH
Click here to add this to my saved trials
Vismodegib in Treating Patients With Recurrent or Refractory Medulloblastoma
A Phase II Clinical Trial Evaluating the Efficacy and Safety of GDC-0449 in Adults With Recurrent or Refractory Medulloblastoma
Status: Enrolling
Updated:  1/28/2016
Pediatric Brain Tumor Consortium
mi
from
Memphis, TN
Vismodegib in Treating Patients With Recurrent or Refractory Medulloblastoma
A Phase II Clinical Trial Evaluating the Efficacy and Safety of GDC-0449 in Adults With Recurrent or Refractory Medulloblastoma
Status: Enrolling
Updated: 1/28/2016
Pediatric Brain Tumor Consortium
mi
from
Memphis, TN
Click here to add this to my saved trials
Vismodegib in Treating Patients With Recurrent or Refractory Medulloblastoma
A Phase II Clinical Trial Evaluating the Efficacy and Safety of GDC-0449 in Adults With Recurrent or Refractory Medulloblastoma
Status: Enrolling
Updated:  1/28/2016
Baylor College of Medicine
mi
from
Houston, TX
Vismodegib in Treating Patients With Recurrent or Refractory Medulloblastoma
A Phase II Clinical Trial Evaluating the Efficacy and Safety of GDC-0449 in Adults With Recurrent or Refractory Medulloblastoma
Status: Enrolling
Updated: 1/28/2016
Baylor College of Medicine
mi
from
Houston, TX
Click here to add this to my saved trials
Cilengitide, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme
A Safety Run-in/Randomized Phase II Trial of EMD 121974 in Conjunction With Concomitant and Adjuvant Temozolomide With Radiation Therapy in Patients With Newly Diagnosed Glioblastoma Multiforme
Status: Enrolling
Updated:  1/28/2016
University of Alabama at Birmingham
mi
from
Birmingham, AL
Cilengitide, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme
A Safety Run-in/Randomized Phase II Trial of EMD 121974 in Conjunction With Concomitant and Adjuvant Temozolomide With Radiation Therapy in Patients With Newly Diagnosed Glioblastoma Multiforme
Status: Enrolling
Updated: 1/28/2016
University of Alabama at Birmingham
mi
from
Birmingham, AL
Click here to add this to my saved trials
Cilengitide, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme
A Safety Run-in/Randomized Phase II Trial of EMD 121974 in Conjunction With Concomitant and Adjuvant Temozolomide With Radiation Therapy in Patients With Newly Diagnosed Glioblastoma Multiforme
Status: Enrolling
Updated:  1/28/2016
Emory University
mi
from
Atlanta, GA
Cilengitide, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme
A Safety Run-in/Randomized Phase II Trial of EMD 121974 in Conjunction With Concomitant and Adjuvant Temozolomide With Radiation Therapy in Patients With Newly Diagnosed Glioblastoma Multiforme
Status: Enrolling
Updated: 1/28/2016
Emory University
mi
from
Atlanta, GA
Click here to add this to my saved trials
Cilengitide, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme
A Safety Run-in/Randomized Phase II Trial of EMD 121974 in Conjunction With Concomitant and Adjuvant Temozolomide With Radiation Therapy in Patients With Newly Diagnosed Glioblastoma Multiforme
Status: Enrolling
Updated:  1/28/2016
Johns Hopkins University
mi
from
Baltimore, MD
Cilengitide, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme
A Safety Run-in/Randomized Phase II Trial of EMD 121974 in Conjunction With Concomitant and Adjuvant Temozolomide With Radiation Therapy in Patients With Newly Diagnosed Glioblastoma Multiforme
Status: Enrolling
Updated: 1/28/2016
Johns Hopkins University
mi
from
Baltimore, MD
Click here to add this to my saved trials
Cilengitide, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme
A Safety Run-in/Randomized Phase II Trial of EMD 121974 in Conjunction With Concomitant and Adjuvant Temozolomide With Radiation Therapy in Patients With Newly Diagnosed Glioblastoma Multiforme
Status: Enrolling
Updated:  1/28/2016
Massachusetts General Hospital
mi
from
Boston, MA
Cilengitide, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme
A Safety Run-in/Randomized Phase II Trial of EMD 121974 in Conjunction With Concomitant and Adjuvant Temozolomide With Radiation Therapy in Patients With Newly Diagnosed Glioblastoma Multiforme
Status: Enrolling
Updated: 1/28/2016
Massachusetts General Hospital
mi
from
Boston, MA
Click here to add this to my saved trials
Cilengitide, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme
A Safety Run-in/Randomized Phase II Trial of EMD 121974 in Conjunction With Concomitant and Adjuvant Temozolomide With Radiation Therapy in Patients With Newly Diagnosed Glioblastoma Multiforme
Status: Enrolling
Updated:  1/28/2016
Henry Ford Hospital
mi
from
Detroit, MI
Cilengitide, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme
A Safety Run-in/Randomized Phase II Trial of EMD 121974 in Conjunction With Concomitant and Adjuvant Temozolomide With Radiation Therapy in Patients With Newly Diagnosed Glioblastoma Multiforme
Status: Enrolling
Updated: 1/28/2016
Henry Ford Hospital
mi
from
Detroit, MI
Click here to add this to my saved trials
Cilengitide, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme
A Safety Run-in/Randomized Phase II Trial of EMD 121974 in Conjunction With Concomitant and Adjuvant Temozolomide With Radiation Therapy in Patients With Newly Diagnosed Glioblastoma Multiforme
Status: Enrolling
Updated:  1/28/2016
Wake Forest University Health Sciences
mi
from
Winston-Salem, NC
Cilengitide, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme
A Safety Run-in/Randomized Phase II Trial of EMD 121974 in Conjunction With Concomitant and Adjuvant Temozolomide With Radiation Therapy in Patients With Newly Diagnosed Glioblastoma Multiforme
Status: Enrolling
Updated: 1/28/2016
Wake Forest University Health Sciences
mi
from
Winston-Salem, NC
Click here to add this to my saved trials
Cilengitide, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme
A Safety Run-in/Randomized Phase II Trial of EMD 121974 in Conjunction With Concomitant and Adjuvant Temozolomide With Radiation Therapy in Patients With Newly Diagnosed Glioblastoma Multiforme
Status: Enrolling
Updated:  1/28/2016
Cleveland Clinic Foundation
mi
from
Cleveland, OH
Cilengitide, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme
A Safety Run-in/Randomized Phase II Trial of EMD 121974 in Conjunction With Concomitant and Adjuvant Temozolomide With Radiation Therapy in Patients With Newly Diagnosed Glioblastoma Multiforme
Status: Enrolling
Updated: 1/28/2016
Cleveland Clinic Foundation
mi
from
Cleveland, OH
Click here to add this to my saved trials
Cilengitide, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme
A Safety Run-in/Randomized Phase II Trial of EMD 121974 in Conjunction With Concomitant and Adjuvant Temozolomide With Radiation Therapy in Patients With Newly Diagnosed Glioblastoma Multiforme
Status: Enrolling
Updated:  1/28/2016
Univ of Pennsylvania
mi
from
Philadelphia, PA
Cilengitide, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme
A Safety Run-in/Randomized Phase II Trial of EMD 121974 in Conjunction With Concomitant and Adjuvant Temozolomide With Radiation Therapy in Patients With Newly Diagnosed Glioblastoma Multiforme
Status: Enrolling
Updated: 1/28/2016
Univ of Pennsylvania
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Standard Dose Bevacizumab Versus Low Dose Bevacizumab Plus Lomustine (CCNU) for Recurrent Glioblastoma Multiforme (GBM)
Randomized Phase II Trial of Standard Dose Bevacizumab Versus Low Dose Bevacizumab Plus Lomustine (CCNU) In Adults With Recurrent Glioblastoma Multiforme
Status: Enrolling
Updated:  1/29/2016
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Standard Dose Bevacizumab Versus Low Dose Bevacizumab Plus Lomustine (CCNU) for Recurrent Glioblastoma Multiforme (GBM)
Randomized Phase II Trial of Standard Dose Bevacizumab Versus Low Dose Bevacizumab Plus Lomustine (CCNU) In Adults With Recurrent Glioblastoma Multiforme
Status: Enrolling
Updated: 1/29/2016
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Click here to add this to my saved trials
Vaccine for Patients With Newly Diagnosed or Recurrent Low-Grade Glioma
A Phase II Clinical Trial Evaluating Autologous Dendritic Cells Pulsed With Tumor Lysate Antigen for the Treatment of Low-grade Glioma
Status: Enrolling
Updated:  1/29/2016
Jonsson Comprehensive Cancer Center
mi
from
Los Angeles, CA
Vaccine for Patients With Newly Diagnosed or Recurrent Low-Grade Glioma
A Phase II Clinical Trial Evaluating Autologous Dendritic Cells Pulsed With Tumor Lysate Antigen for the Treatment of Low-grade Glioma
Status: Enrolling
Updated: 1/29/2016
Jonsson Comprehensive Cancer Center
mi
from
Los Angeles, CA
Click here to add this to my saved trials
ABT-751 in Treating Children With Neuroblastoma That Has Relapsed or Not Responded to Previous Treatment
A Phase II Study of ABT-751, an Orally Bioavailable Tubulin Binding Agent, in Children With Relapsed or Refractory Neuroblastoma
Status: Enrolling
Updated:  1/29/2016
University of Alabama at Birmingham
mi
from
Birmingham, AL
ABT-751 in Treating Children With Neuroblastoma That Has Relapsed or Not Responded to Previous Treatment
A Phase II Study of ABT-751, an Orally Bioavailable Tubulin Binding Agent, in Children With Relapsed or Refractory Neuroblastoma
Status: Enrolling
Updated: 1/29/2016
University of Alabama at Birmingham
mi
from
Birmingham, AL
Click here to add this to my saved trials
ABT-751 in Treating Children With Neuroblastoma That Has Relapsed or Not Responded to Previous Treatment
A Phase II Study of ABT-751, an Orally Bioavailable Tubulin Binding Agent, in Children With Relapsed or Refractory Neuroblastoma
Status: Enrolling
Updated:  1/29/2016
University of Chicago Comprehensive Cancer Center
mi
from
Chicago, IL
ABT-751 in Treating Children With Neuroblastoma That Has Relapsed or Not Responded to Previous Treatment
A Phase II Study of ABT-751, an Orally Bioavailable Tubulin Binding Agent, in Children With Relapsed or Refractory Neuroblastoma
Status: Enrolling
Updated: 1/29/2016
University of Chicago Comprehensive Cancer Center
mi
from
Chicago, IL
Click here to add this to my saved trials
ABT-751 in Treating Children With Neuroblastoma That Has Relapsed or Not Responded to Previous Treatment
A Phase II Study of ABT-751, an Orally Bioavailable Tubulin Binding Agent, in Children With Relapsed or Refractory Neuroblastoma
Status: Enrolling
Updated:  1/29/2016
Dana-Farber Cancer Institute
mi
from
Boston, MA
ABT-751 in Treating Children With Neuroblastoma That Has Relapsed or Not Responded to Previous Treatment
A Phase II Study of ABT-751, an Orally Bioavailable Tubulin Binding Agent, in Children With Relapsed or Refractory Neuroblastoma
Status: Enrolling
Updated: 1/29/2016
Dana-Farber Cancer Institute
mi
from
Boston, MA
Click here to add this to my saved trials
ABT-751 in Treating Children With Neuroblastoma That Has Relapsed or Not Responded to Previous Treatment
A Phase II Study of ABT-751, an Orally Bioavailable Tubulin Binding Agent, in Children With Relapsed or Refractory Neuroblastoma
Status: Enrolling
Updated:  1/29/2016
C S Mott Children's Hospital
mi
from
Ann Arbor, MI
ABT-751 in Treating Children With Neuroblastoma That Has Relapsed or Not Responded to Previous Treatment
A Phase II Study of ABT-751, an Orally Bioavailable Tubulin Binding Agent, in Children With Relapsed or Refractory Neuroblastoma
Status: Enrolling
Updated: 1/29/2016
C S Mott Children's Hospital
mi
from
Ann Arbor, MI
Click here to add this to my saved trials
ABT-751 in Treating Children With Neuroblastoma That Has Relapsed or Not Responded to Previous Treatment
A Phase II Study of ABT-751, an Orally Bioavailable Tubulin Binding Agent, in Children With Relapsed or Refractory Neuroblastoma
Status: Enrolling
Updated:  1/29/2016
Washington University School of Medicine
mi
from
Saint Louis, MO
ABT-751 in Treating Children With Neuroblastoma That Has Relapsed or Not Responded to Previous Treatment
A Phase II Study of ABT-751, an Orally Bioavailable Tubulin Binding Agent, in Children With Relapsed or Refractory Neuroblastoma
Status: Enrolling
Updated: 1/29/2016
Washington University School of Medicine
mi
from
Saint Louis, MO
Click here to add this to my saved trials